A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379.
Blood. 2021.
PMID: 34653242
Free PMC article.
Clinical Trial.